<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35727573</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6211</ISSN><JournalIssue CitedMedium="Internet"><Volume>176</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA pediatrics</Title><ISOAbbreviation>JAMA Pediatr</ISOAbbreviation></Journal><ArticleTitle>Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>860</StartPage><EndPage>866</EndPage><MedlinePgn>860-866</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapediatrics.2022.1973</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The efficacy of multispecies probiotic formulations in the prevention of antibiotic-associated diarrhea (AAD) remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">To assess the effect of a multispecies probiotic on the risk of AAD in children.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This randomized, quadruple-blind, placebo-controlled trial was conducted from February 2018 to May 2021 in a multicenter, mixed setting (inpatients and outpatients). Patients were followed up throughout the intervention period. Eligibility criteria included age 3 months to 18 years, recruitment within 24 hours following initiation of broad-spectrum systemic antibiotics, and signed informed consent. In total, 646 eligible patients were approached and 350 patients took part in the trial.</AbstractText><AbstractText Label="INTERVENTIONS">A multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, L acidophilus W55, Lacticaseibacillus paracasei W20, Lactiplantibacillus plantarum W62, Lacticaseibacillus rhamnosus W71, and Ligilactobacillus salivarius W24, for a total dose of 10 billion colony-forming units daily, for the duration of antibiotic treatment and for 7 days after.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was AAD, defined as 3 or more loose or watery stools per day in a 24-hour period, caused either by Clostridioides difficile or of otherwise unexplained etiology, after testing for common diarrheal pathogens. The secondary outcomes included diarrhea regardless of the etiology, diarrhea duration, and predefined diarrhea complications.</AbstractText><AbstractText Label="RESULTS">A total of 350 children (192 boys and 158 girls; mean [range] age, 50 [3-212] months) were randomized and 313 were included in the intention-to-treat analysis. Compared with placebo (n&#x2009;=&#x2009;155), the probiotic (n&#x2009;=&#x2009;158) had no effect on risk of AAD (relative risk [RR], 0.81; 95% CI, 0.49-1.33). However, children in the probiotic group had a lower risk of diarrhea regardless of the etiology (RR, 0.65; 95% CI, 0.44-0.94). No differences were observed between the groups for most of the secondary outcomes, including adverse events.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">A multispecies probiotic did not reduce the risk of AAD in children when analyzed according to the most stringent definition. However, it reduced the overall risk of diarrhea during and for 7 days after antibiotic treatment. Our study also shows that the AAD definition has a significant effect on clinical trial results and their interpretation.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT03334604.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lukasik</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dierikx</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Academic Medical Centre, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besseling-van der Vaart</LastName><ForeName>Isolde</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Winclove Probiotics B.V., Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Meij</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatric Gastroenterology, Emma Children's Hospital, Amsterdam UMC, Academic Medical Centre, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szajewska</LastName><ForeName>Hania</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Multispecies Probiotic in AAD Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03334604</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Pediatr</MedlineTA><NlmUniqueID>101589544</NlmUniqueID><ISSNLinking>2168-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Pediatr. 2022 Sep 1;176(9):948. doi: 10.1001/jamapediatrics.2022.2527.</RefSource><PMID Version="1">35788632</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="Y">Diarrhea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr &#x141;ukasik reported nonfinancial support from Winclove Probiotics B.V. Dr Dierikx reported grants and nonfinancial support from Winclove Probiotics B.V. Dr de Meij reported grants and nonfinancial support from Winclove B.V. Dr Szajewska reported nonfinancial support from Winclove B.V.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>van der Schoor</LastName><ForeName>Sophie R D</ForeName><Initials>SRD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chegary</LastName><ForeName>Malika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koning</LastName><ForeName>Catharina Karen J M</ForeName><Initials>CKJM</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35727573</ArticleId><ArticleId IdType="pmc">PMC9214631</ArticleId><ArticleId IdType="doi">10.1001/jamapediatrics.2022.1973</ArticleId><ArticleId IdType="pii">2793114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Turck D, Bernet JP, Marx J, et al. . Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr. 2003;37(1):22-26. doi:10.1097/00005176-200307000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005176-200307000-00004</ArticleId><ArticleId IdType="pubmed">12827001</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4(4):CD004827. doi:10.1002/14651858.CD004827.pub5</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004827.pub5</ArticleId><ArticleId IdType="pmc">PMC6490796</ArticleId><ArticleId IdType="pubmed">31039287</ArticleId></ArticleIdList></Reference><Reference><Citation>Szajewska H, Canani RB, Guarino A, et al. ; ESPGHAN Working Group for ProbioticsPrebiotics . Probiotics for the prevention of antibiotic-associated diarrhea in children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506. doi:10.1097/MPG.0000000000001081</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001081</ArticleId><ArticleId IdType="pubmed">26756877</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W, Chen C, Wen T, Zhao Q. Probiotics for the prevention of antibiotic-associated diarrhea in adults: a meta-analysis of randomized placebo-controlled trials. J Clin Gastroenterol. 2021;55(6):469-480. doi:10.1097/MCG.0000000000001464</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000001464</ArticleId><ArticleId IdType="pmc">PMC8183490</ArticleId><ArticleId IdType="pubmed">33234881</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;ukasik J, Guo Q, Boulos L, Szajewska H, Johnston BC. Probiotics for the prevention of antibiotic-associated adverse events in children-a scoping review to inform development of a core outcome set. PLoS One. 2020;15(5):e0228824. doi:10.1371/journal.pone.0228824</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0228824</ArticleId><ArticleId IdType="pmc">PMC7259577</ArticleId><ArticleId IdType="pubmed">32469907</ArticleId></ArticleIdList></Reference><Reference><Citation>Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol. 2004;42(3):1203-1206. doi:10.1128/JCM.42.3.1203-1206.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.42.3.1203-1206.2004</ArticleId><ArticleId IdType="pmc">PMC356823</ArticleId><ArticleId IdType="pubmed">15004076</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563-578. doi:10.2217/17460913.3.5.563</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/17460913.3.5.563</ArticleId><ArticleId IdType="pubmed">18811240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, et al. . Expert consensus document. The International Scientific Association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad K, Fatemeh F, Mehri N, Maryam S. Probiotics for the treatment of pediatric helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr. 2013;23(1):79-84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3574996</ArticleId><ArticleId IdType="pubmed">23446685</ArticleId></ArticleIdList></Reference><Reference><Citation>Saneeyan H, Layegh S, Rahimi H. Effectiveness of probiotic on treatment of Helicobacter pylori infection in children. Majallah-i Danishkadah-i Pizishki-i Isfahan. 2011;146(29):882-889.</Citation></Reference><Reference><Citation>Merenstein DJ, Foster J, D&#x2019;Amico F. A randomized clinical trial measuring the influence of kefir on antibiotic-associated diarrhea: the Measuring the Influence of Kefir (MILK) study. Arch Pediatr Adolesc Med. 2009;163(8):750-754. doi:10.1001/archpediatrics.2009.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpediatrics.2009.119</ArticleId><ArticleId IdType="pubmed">19652108</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway S, Hart A, Clark A, Harvey I. Does eating yogurt prevent antibiotic-associated diarrhoea? a placebo-controlled randomised controlled trial in general practice. Br J Gen Pract. 2007;57(545):953-959. doi:10.3399/096016407782604811</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/096016407782604811</ArticleId><ArticleId IdType="pmc">PMC2084134</ArticleId><ArticleId IdType="pubmed">18252070</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharnai S, Nirmala P, Ramanathan R, Vanitha S. Comparative study of efficacy and safety of azithromycin alone and in combination with probiotic in the treatment of impetigo in children. Int J Curr Pharm Res. 2017;9(6):52-55. doi:10.22159/ijcpr.2017v9i6.23429</Citation><ArticleIdList><ArticleId IdType="doi">10.22159/ijcpr.2017v9i6.23429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakordonets L, Tolstanova G, Yankovskiy D, Dyment H, Kramarev S. Different regimes of multiprobiotic for prevention of immediate and delayed side effects of antibiotic therapy In children. Res J Pharm Biol Chem Sci. 2016;7(3):2194-2201.</Citation></Reference><Reference><Citation>Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM, Stockbr&#xfc;gger RW. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. Am J Gastroenterol. 2008;103(1):178-189. doi:10.1111/j.1572-0241.2007.01547.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2007.01547.x</ArticleId><ArticleId IdType="pubmed">17900321</ArticleId></ArticleIdList></Reference><Reference><Citation>Koning CJ, Jonkers D, Smidt H, et al. . The effect of a multispecies probiotic on the composition of the faecal microbiota and bowel habits in chronic obstructive pulmonary disease patients treated with antibiotics. Br J Nutr. 2010;103(10):1452-1460. doi:10.1017/S0007114509993497</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114509993497</ArticleId><ArticleId IdType="pubmed">20021703</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x141;ukasik J, Szajewska H. Effect of a multispecies probiotic on reducing the incidence of antibiotic-associated diarrhoea in children: a protocol for a randomised controlled trial. BMJ Open. 2018;8(5):e021214. doi:10.1136/bmjopen-2017-021214</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-021214</ArticleId><ArticleId IdType="pmc">PMC5988056</ArticleId><ArticleId IdType="pubmed">29866789</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D; CONSORT Group . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi:10.1136/bmj.c332</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c332</ArticleId><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanma A, Puttemans K, Deneyer M, Benninga MA, Vandenplas Y. Amsterdam infant stool scale is more useful for assessing children who have not been toilet trained than Bristol Stool Scale. Acta Paediatr. 2014;103(2):e91-e92. doi:10.1111/apa.12422</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.12422</ArticleId><ArticleId IdType="pubmed">24107091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SJ, Heaton KW. Stool Form Scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920-924. doi:10.3109/00365529709011203</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365529709011203</ArticleId><ArticleId IdType="pubmed">9299672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruszczy&#x144;ski M, Radzikowski A, Szajewska H. Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther. 2008;28(1):154-161. doi:10.1111/j.1365-2036.2008.03714.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03714.x</ArticleId><ArticleId IdType="pubmed">18410562</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(5):583-590. doi:10.1111/j.1365-2036.2005.02356.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02356.x</ArticleId><ArticleId IdType="pubmed">15740542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials&#x2014;a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162. doi:10.1186/s12874-017-0442-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-017-0442-1</ArticleId><ArticleId IdType="pmc">PMC5717805</ArticleId><ArticleId IdType="pubmed">29207961</ArticleId></ArticleIdList></Reference><Reference><Citation>Akl EA, Briel M, You JJ, et al. . Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ. 2012;344:e2809. doi:10.1136/bmj.e2809</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e2809</ArticleId><ArticleId IdType="pubmed">22611167</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozalbo-Rovira R, Rubio-Del-Campo A, Santiso-Bell&#xf3;n C, et al. . Interaction of intestinal bacteria with human rotavirus during infection in children. Int J Mol Sci. 2021;22(3):1010. doi:10.3390/ijms22031010</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031010</ArticleId><ArticleId IdType="pmc">PMC7864024</ArticleId><ArticleId IdType="pubmed">33498321</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchiyama R, Chassaing B, Zhang B, Gewirtz AT. Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity. J Infect Dis. 2014;210(2):171-182. doi:10.1093/infdis/jiu037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu037</ArticleId><ArticleId IdType="pmc">PMC4399425</ArticleId><ArticleId IdType="pubmed">24436449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojsak I, Szajewska H, Canani RB, et al. ; ESPGHAN Working Group for Probiotics/Prebiotics . Probiotics for the prevention of nosocomial diarrhea in children. J Pediatr Gastroenterol Nutr. 2018;66(1):3-9. doi:10.1097/MPG.0000000000001637</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001637</ArticleId><ArticleId IdType="pubmed">28574970</ArticleId></ArticleIdList></Reference><Reference><Citation>Za&#x142;&#x119;ski A, Banasiuk M, Karpierz K, Kuchar E, Podsiad&#x142;y E. The clinical course of gastroenteritis due to nosocomial and community acquired norovirus infections in immunocompromised and immunocompetent children&#x2014;single center experience. Przegl Epidemiol. 2020;74(1):23-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">32500981</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogilvie I, Khoury H, Goetghebeur MM, El Khoury AC, Giaquinto C. Burden of community-acquired and nosocomial rotavirus gastroenteritis in the pediatric population of Western Europe: a scoping review. BMC Infect Dis. 2012;12:62. doi:10.1186/1471-2334-12-62</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-12-62</ArticleId><ArticleId IdType="pmc">PMC3342230</ArticleId><ArticleId IdType="pubmed">22429601</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; European Society for Pediatric Infectious Diseases . European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132-152. doi:10.1097/MPG.0000000000000375</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000375</ArticleId><ArticleId IdType="pubmed">24739189</ArticleId></ArticleIdList></Reference><Reference><Citation>Groenwold RH, Moons KG, Vandenbroucke JP. Randomized trials with missing outcome data: how to analyze and what to report. CMAJ. 2014;186(15):1153-1157. doi:10.1503/cmaj.131353</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.131353</ArticleId><ArticleId IdType="pmc">PMC4203602</ArticleId><ArticleId IdType="pubmed">24778353</ArticleId></ArticleIdList></Reference><Reference><Citation>Little RJ, D&#x2019;Agostino R, Cohen ML, et al. . The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355-1360. doi:10.1056/NEJMsr1203730</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr1203730</ArticleId><ArticleId IdType="pmc">PMC3771340</ArticleId><ArticleId IdType="pubmed">23034025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby A, Iturriza-G&#xf3;mara M. Norovirus diagnostics: options, applications and interpretations. Expert Rev Anti Infect Ther. 2012;10(4):423-433. doi:10.1586/eri.12.21</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.12.21</ArticleId><ArticleId IdType="pubmed">22512752</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>